{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:08:04Z","timestamp":1780481284279,"version":"3.54.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,6,23]]},"abstract":"<jats:p>Omadacycline, a novel aminomethylcycline antibiotic with activity against Gram-positive and -negative organisms, including tetracycline-resistant pathogens, received FDA approval in October 2018 for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). A previously developed population pharmacokinetic (PK) model based on phase 1 intravenous and oral PK data was refined using data from infected patients. Data from 10 phase 1 studies used to develop the previous model were pooled with data from three additional phase 1 studies, a phase 1b uncomplicated urinary tract infection study, one phase 3 CABP study, and two phase 3 ABSSSI studies.<\/jats:p>","DOI":"10.1128\/aac.02263-19","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T14:26:24Z","timestamp":1587651984000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data"],"prefix":"10.1128","volume":"64","author":[{"given":"Elizabeth A.","family":"Lakota","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Van Wart","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trang","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Tzanis","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Courtney","family":"Safir","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith N.","family":"Steenbergen","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.02.017"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02262-18"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-18"},{"key":"e_1_3_3_8_2","volume-title":"NUZYRA (omadacycline) package insert","author":"Paratek Pharmaceuticals, Inc","year":"2020","unstructured":"Paratek Pharmaceuticals, Inc. 2020. NUZYRA (omadacycline) package insert. Paratek Pharmaceuticals, Inc, Boston, MA."},{"key":"e_1_3_3_9_2","unstructured":"Van Wart SA Manley A Bhavnani SM Tanaka K Loh E Rubino CM Tzanis E Ambrose PG. 2016. Population pharmacokinetics of omadacycline following intravenous or oral administration to phase 1 subjects. Abstr Euro Congr Clin Microbiol Infect Dis poster P1320."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-17"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02083-18"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_3_15_2","unstructured":"Noel GJ Draper M Hait H Tanaka SK. 2012. Safety and efficacy of PTK0796 (omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI) poster P694. Abstr Euro Congr Clin Microbiol Infect Dis."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_3_18_2","unstructured":"Villano S Tzanis E Tanaka K. 2016. In vitro protein binding with omadacycline a first in class aminomethylcycline antibiotic. Microbe 2016 abstr 518."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1065"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1098"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/383320"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02329-18"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1_7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781118784860.ch8"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0000168206.59873.80"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.028"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.019"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx541"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa049"},{"key":"e_1_3_3_30_2","unstructured":"Bhavnani SM Hammel JP Lakota EA Bader JC Bulik CC VanScoy BD Rubino CM Huband MD Steenbergen JN Ambrose PG. 2018. Pharmacokinetic-pharmacodynamic target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia for Streptococcus pneumoniae and Haemophilus influenzae . Microbe 2018 poster Saturday 625."},{"key":"e_1_3_3_31_2","unstructured":"Bhavnani SM Hammel JP Lakota EA Liolios K Rubino CM Steenbergen JN Friedrich L Tzanis E Ambrose PG. 2019. Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections. Euro Congr Clin Microbiol Infect Dis poster P1944."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.60.2.532"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02263-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02263-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:47:13Z","timestamp":1645480033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02263-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,6,23]]}},"alternative-id":["10.1128\/AAC.02263-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02263-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"2019-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02263-19"}}